Cargando…

Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis

BACKGROUND: Worse prognosis of endometrial cancers (EC) in tamoxifen‐treated women compared to non‐tamoxifen‐treated women been proposed. The relationship between tamoxifen treatment of breast cancer (BC) and the risk of EC is controversial and there is no agreement between publication results on th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghanavati, Matin, Khorshidi, Yasaman, Shadnoush, Mahdi, Akbari, Mohammad Esmaeil, Ardehali, Seyed Hossein, Chavarri‐Guerra, Yanin, Akbari, Atieh, Barragan‐Carrillo, Regina, Amin Amlashi, Manoochehr, Javid, Zeinab, Rahmani, Jamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075294/
https://www.ncbi.nlm.nih.gov/pubmed/36916539
http://dx.doi.org/10.1002/cnr2.1806
_version_ 1785019893723168768
author Ghanavati, Matin
Khorshidi, Yasaman
Shadnoush, Mahdi
Akbari, Mohammad Esmaeil
Ardehali, Seyed Hossein
Chavarri‐Guerra, Yanin
Akbari, Atieh
Barragan‐Carrillo, Regina
Amin Amlashi, Manoochehr
Javid, Zeinab
Rahmani, Jamal
author_facet Ghanavati, Matin
Khorshidi, Yasaman
Shadnoush, Mahdi
Akbari, Mohammad Esmaeil
Ardehali, Seyed Hossein
Chavarri‐Guerra, Yanin
Akbari, Atieh
Barragan‐Carrillo, Regina
Amin Amlashi, Manoochehr
Javid, Zeinab
Rahmani, Jamal
author_sort Ghanavati, Matin
collection PubMed
description BACKGROUND: Worse prognosis of endometrial cancers (EC) in tamoxifen‐treated women compared to non‐tamoxifen‐treated women been proposed. The relationship between tamoxifen treatment of breast cancer (BC) and the risk of EC is controversial and there is no agreement between publication results on this issue (the answer to all comments provided in the page 2 of manuscript). The aim of this study is investigation the association between tamoxifen treatment and the risk of EC in patients with BC. METHODS AND RESULTS: We conducted a comprehensive search with related keywords in MEDLINE/PubMed, SCOPUS, and Web of Science databases until April 16, 2022. Random‐effects model (DerSimonian and Laird) was used to pool risk ratios (RRs) with 95% confidence intervals (CIs) of EC. Dose, cumulative dose, and duration‐response analysis were performed in linear and non‐linear states. Twenty‐six studies reported a relation between tamoxifen treatment and risk of EC in patients with BC. Results showed a direct relationship between tamoxifen use and EC (RR: 2.03, 95% CI: 1.68–2.45; I2:76%). By increase the age of participants, the risk of EC was decrease (coef = −.0206), although this was not statistically significant (p = .37). Linear dose–response model indicated a direct significant association between dose and duration use of tamoxifen and EC (dose: exe(b) = 1.019, p = .001; duration: exe(b) = 1.014, p = .001). Non‐linear dose–response analysis confirmed linear analysis. CONCLUSION: This study highlights that tamoxifen use is a significant risk factor related to the incidence of EC in patients with BC.
format Online
Article
Text
id pubmed-10075294
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100752942023-04-06 Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis Ghanavati, Matin Khorshidi, Yasaman Shadnoush, Mahdi Akbari, Mohammad Esmaeil Ardehali, Seyed Hossein Chavarri‐Guerra, Yanin Akbari, Atieh Barragan‐Carrillo, Regina Amin Amlashi, Manoochehr Javid, Zeinab Rahmani, Jamal Cancer Rep (Hoboken) Review BACKGROUND: Worse prognosis of endometrial cancers (EC) in tamoxifen‐treated women compared to non‐tamoxifen‐treated women been proposed. The relationship between tamoxifen treatment of breast cancer (BC) and the risk of EC is controversial and there is no agreement between publication results on this issue (the answer to all comments provided in the page 2 of manuscript). The aim of this study is investigation the association between tamoxifen treatment and the risk of EC in patients with BC. METHODS AND RESULTS: We conducted a comprehensive search with related keywords in MEDLINE/PubMed, SCOPUS, and Web of Science databases until April 16, 2022. Random‐effects model (DerSimonian and Laird) was used to pool risk ratios (RRs) with 95% confidence intervals (CIs) of EC. Dose, cumulative dose, and duration‐response analysis were performed in linear and non‐linear states. Twenty‐six studies reported a relation between tamoxifen treatment and risk of EC in patients with BC. Results showed a direct relationship between tamoxifen use and EC (RR: 2.03, 95% CI: 1.68–2.45; I2:76%). By increase the age of participants, the risk of EC was decrease (coef = −.0206), although this was not statistically significant (p = .37). Linear dose–response model indicated a direct significant association between dose and duration use of tamoxifen and EC (dose: exe(b) = 1.019, p = .001; duration: exe(b) = 1.014, p = .001). Non‐linear dose–response analysis confirmed linear analysis. CONCLUSION: This study highlights that tamoxifen use is a significant risk factor related to the incidence of EC in patients with BC. John Wiley and Sons Inc. 2023-03-14 /pmc/articles/PMC10075294/ /pubmed/36916539 http://dx.doi.org/10.1002/cnr2.1806 Text en © 2023 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Ghanavati, Matin
Khorshidi, Yasaman
Shadnoush, Mahdi
Akbari, Mohammad Esmaeil
Ardehali, Seyed Hossein
Chavarri‐Guerra, Yanin
Akbari, Atieh
Barragan‐Carrillo, Regina
Amin Amlashi, Manoochehr
Javid, Zeinab
Rahmani, Jamal
Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis
title Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis
title_full Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis
title_fullStr Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis
title_full_unstemmed Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis
title_short Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis
title_sort tamoxifen use and risk of endometrial cancer in breast cancer patients: a systematic review and dose–response meta‐analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075294/
https://www.ncbi.nlm.nih.gov/pubmed/36916539
http://dx.doi.org/10.1002/cnr2.1806
work_keys_str_mv AT ghanavatimatin tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis
AT khorshidiyasaman tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis
AT shadnoushmahdi tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis
AT akbarimohammadesmaeil tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis
AT ardehaliseyedhossein tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis
AT chavarriguerrayanin tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis
AT akbariatieh tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis
AT barragancarrilloregina tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis
AT aminamlashimanoochehr tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis
AT javidzeinab tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis
AT rahmanijamal tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis